PMID- 36268341
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221022
IS  - 2049-0801 (Print)
IS  - 2049-0801 (Electronic)
IS  - 2049-0801 (Linking)
VI  - 82
DP  - 2022 Oct
TI  - Alectinib-associated pneumoperitoneum in stage IV non-small cell lung cancer - A 
      case report.
PG  - 104601
LID - 10.1016/j.amsu.2022.104601 [doi]
LID - 104601
AB  - INTRODUCTION AND IMPORTANCE: Alectinib, a highly potent, highly selective, 
      brain-penetrant anaplastic lymphoma kinase (ALK) inhibitor is now the first line 
      therapy for patients with metastatic ALK-positive non small cell lung cancer 
      (NSCLC). CASE PRESENTATION: We report a rare case of pneumoperitoneum following 
      alectinib initiation for metastatic non small cell lung cancer in a 74-year-old 
      African American female. Patient developed abdominal pain approximately 2 weeks 
      after starting alectinib. She was hemodynamically stable, and imaging revealed 
      pneumoperitoneum. Patient was successfully managed non-operatively. CLINICAL 
      DISCUSSION: Gastrointestinal perforation presenting as pneumoperitoneum is a very 
      rare complication of alectinib. To our knowledge our patient is only the second 
      case to be reported in the literature since its approval. The complication is 
      likely attributable to the rapid tumor regression in the gastrointestinal tract. 
      Non-operative management should be attempted if possible. CONCLUSION: Oncologists 
      should be aware of the risk of gastrointestinal perforation when initiating 
      cytotoxic chemotherapy on patients with metastatic NSCLC. A multidisciplinary 
      approach is critical in appropriately individualizing care in this patient 
      population.
CI  - (c) 2022 The Author(s).
FAU - Maina, Renee M
AU  - Maina RM
AD  - Department of Surgery, University of Tennessee Health Science Center, Memphis, 
      TN, USA.
FAU - Rader, Caroline A
AU  - Rader CA
AD  - College of Medicine, University of Tennessee Health Science Center, Memphis, TN, 
      USA.
FAU - Muenyi, Clarisse S
AU  - Muenyi CS
AD  - Department of Surgery, University of Tennessee Health Science Center, Memphis, 
      TN, USA.
FAU - Battini, Ramakrishna
AU  - Battini R
AD  - West Cancer Center, Memphis, TN, USA.
FAU - Zalamea, Nia N
AU  - Zalamea NN
AD  - Department of Surgery, University of Tennessee Health Science Center, Memphis, 
      TN, USA.
FAU - Foretia, Denis A
AU  - Foretia DA
AD  - Department of Surgery, University of Tennessee Health Science Center, Memphis, 
      TN, USA.
LA  - eng
PT  - Case Reports
DEP - 20220909
PL  - England
TA  - Ann Med Surg (Lond)
JT  - Annals of medicine and surgery (2012)
JID - 101616869
PMC - PMC9577531
OTO - NOTNLM
OT  - ALK, anaplastic lymphoma kinase
OT  - Alectinib
OT  - CNS, central nervous system
OT  - CT, computed tomography
OT  - Case report
OT  - Chemotherapy
OT  - GI, gastrointestinal
OT  - Gastrointestinal perforation
OT  - NSCLC, non small cell lung cancer
OT  - Non-small cell lung cancer
OT  - Pneumoperitoneum
EDAT- 2022/10/22 06:00
MHDA- 2022/10/22 06:01
PMCR- 2022/09/09
CRDT- 2022/10/21 03:13
PHST- 2022/07/16 00:00 [received]
PHST- 2022/09/02 00:00 [revised]
PHST- 2022/09/04 00:00 [accepted]
PHST- 2022/10/21 03:13 [entrez]
PHST- 2022/10/22 06:00 [pubmed]
PHST- 2022/10/22 06:01 [medline]
PHST- 2022/09/09 00:00 [pmc-release]
AID - S2049-0801(22)01361-9 [pii]
AID - 104601 [pii]
AID - 10.1016/j.amsu.2022.104601 [doi]
PST - epublish
SO  - Ann Med Surg (Lond). 2022 Sep 9;82:104601. doi: 10.1016/j.amsu.2022.104601. 
      eCollection 2022 Oct.